Letairis Approved for Treatment of Pulmonary Arterial Hypertension in Combination with Adcirca
October 5, 2015 - The U.S. Food and Drug Administration approved Letairis (ambrisetan) manufacturered by Gilead. Letairis is an endothelin receptor antagonist for use in combination with Adcirca (tadalafil) (manufactured by Lilly), a phosphodiesterase type 5(PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to reduce the risk of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Letairis was previously approved in 2007 as monotherapy for PAH, while Adcirca was previously approved in 2009 for PAH. It is a well-established clinical practice for the use of combination drugs to treat PAH.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.